Thiosemicarbazides: Updates on Antivirals Strategy

Author(s): Alok Kumar Moharana, Rudra Narayan Dash, Bharat Bhusan Subudhi*

Journal Name: Mini-Reviews in Medicinal Chemistry

Volume 20 , Issue 20 , 2020

Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


The challenges of viral infection have increased in recent decades due to the emergence of resistance, cross-resistance and drying up of antiviral drug discovery. Many neglected tropical viruses including the chikungunya virus, dengue virus & Japanese encephalitis virus have gradually become global pathogens. This has further increased the burden of viral infection which necessitates the continuous development of antiviral therapy. The antiviral chemistry began with the development of thiosemicarbazide derived thiosemicarbazones as antiviral. Although very few thiosemicarbazides have progressed into clinical application, it still inspires antiviral development. During last 3 decades (1990- 2020), several efforts have been made to develop suitable antiviral by using thiosemicarbazide scaffold. Its hybridization with other pharmacophores has been used as a strategy to enhance safety and efficacy. Cyclization and substitution of thiosemicarbazides have also been used to develop potent antiviral. With the ability to form coordinate bonds, thiosemicarbazides have been used either as metal complex or chelator against viruses. This work is an attempt to systematically review the research on the use of thiosemicarbazides as an antiviral scaffold. It also reviews the structure-activity relationship and translational suitability of thiosemicarbazide derived compounds.

Keywords: Thiosemicarbazide, thiosemicarbazone, virus, antiviral, chikungunya virus, SAR, viral infection.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2020
Published on: 14 January, 2021
Page: [2135 - 2152]
Pages: 18
DOI: 10.2174/1389557520666200818212408
Price: $65

Article Metrics

PDF: 24